Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance - Test2 - elhamkhani - TriplyDB

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

http://www.wikidata.org/entity/Q28250818

about

Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs Prediction of psilocybin response in healthy volunteers Psychometric evaluation of the altered states of consciousness rating scale (OAV)Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials Is it time to revisit the role of psychedelic drugs in enhancing human creativity?Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice Human hallucinogen research: guidelines for safety Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness The behavioral pharmacology of hallucinogens Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years Legal highs: staying on top of the flood of novel psychoactive substances Recent advances in the neuropsychopharmacology of serotonergic hallucinogens The subjective experience of acute, experimentally-induced Salvia divinorum inebriation Illicit Use of LSD or Psilocybin, but not MDMA or Nonpsychedelic Drugs, is Associated with Mystical Experiences in a Dose-Dependent Manner Psychedelics "Research chemicals": tryptamine and phenethylamine use among high-risk youth.LSD enhances the emotional response to music.LSD-induced entropic brain activity predicts subsequent personality change.Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution.Animal models of serotonergic psychedelics.Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin Pharmacological properties and discriminative stimulus effects of a novel and selective 5-HT2 receptor agonist AL-38022A [(S)-2-(8,9-dihydro-7H-pyrano[2,3-g]indazol-1-yl)-1-methylethylamine].Peak experiences of psilocybin users and non-users.Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.Alterations of consciousness and mystical-type experiences after acute LSD in humans.Cross-national differences in clinically significant cannabis problems: epidemiologic evidence from 'cannabis-only' smokers in the United States, Mexico, and Colombia.Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.Therapeutic infusions of ketamine: do the psychoactive effects matter?The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users.The emerging role of meditation in addressing psychiatric illness, with a focus on substance use disorders

P2860

Q21091087-8AEC16B9-4C5A-40CD-BBC5-490068A82166 Q21129387-CC622D67-379A-4299-99B0-1263D10C7A7E Q21134798-0C666699-3AAB-429B-9C86-F93B3BC77B4E Q21136163-EE17D050-D7AD-4B77-A3C6-F0CA31EB6935 Q22241778-DB16903E-83BA-4CFE-A165-3D888E03362F Q22241828-AD4527D7-757A-46C7-B809-4CB244A1ED27 Q22241829-4EA48A3F-5BD7-4839-8502-F4FBD78477DD Q24594834-DE685CD2-76C5-457C-869E-89FBD2EA85CF Q24600704-DDCF6714-E16D-42E3-81CF-F7C1AE225B77 Q24606321-CE07BAB9-3F7F-421D-8282-866FB10569ED Q24613764-FBC2BE3D-ACCE-49A2-93DA-CEEC6466692C Q24616738-9C4FF3F0-B7D4-4CB6-8ABD-9BFC6727CBB2 Q24620135-B19A4B9E-9278-4819-AAD6-262CE3EE8452 Q24620764-00D2B87B-583D-445D-9348-089DF3C08F9E Q24633222-25DA8661-911B-4F1A-A988-54620FEE6CD5 Q24634013-639B4B21-193E-44C6-94B5-A3C733DB6485 Q24645656-00E4BFE3-A741-4BF9-B862-15DD77464958 Q26746137-105486D9-F512-4EF1-83AE-A0CC7A468DB4 Q26799231-49621C27-5834-44DB-AD2C-F71554D1D900 Q27027381-B10791E5-BA29-462C-8EB0-DD32EF6BB000 Q28257248-D68260F8-3C31-484C-A04F-0F51614A394F Q29040486-51B2C7D6-7E22-445C-B238-A32368DD23D6 Q30359998-2A8F7313-1FA3-4E0F-B849-C8CF35AA21DA Q30368441-8E551179-093B-4564-A41D-96CCE0F31DCE Q30377709-46F54B18-F734-4246-A507-7884A87E0F74 Q30387757-4F9EF594-DBDF-49A7-A764-17342C2B51B1 Q30402789-C794D97A-4E83-42DD-B272-384E09C28D65 Q30444312-0E3BF1CC-2160-4986-A909-EAEF4909C851 Q30531761-F08BD383-0936-4BC9-ADE1-0013EDF76133 Q30544127-E11939C2-C03D-4B65-B97D-4289D47AA9F0 Q30559498-26443F8D-A547-44C8-A908-ED888A1E64AA Q30833479-5F2F7CE8-9BB5-42CF-B98D-706CEF3ACB8F Q30843010-077F752C-1416-4ADD-A7A6-C980750235C6 Q30847957-2AA25B25-8D58-42F6-BEAC-59746C4981FB Q33544900-347E3F9E-7333-4E2B-9C24-F89B9077148F Q33863459-2A24D266-AAFC-46AE-AECC-0D6635FFDEFB Q33880853-ED893E8A-0748-4C71-94AD-78FCB3A00655 Q33926787-8DE16F8A-7B99-4F67-AEFB-5222134B08B6 Q33937677-31BE5B34-81E2-47E9-881F-866071054C80 Q34018674-C62231A3-579C-4BDD-BBAA-6969455E0FD1

P2860

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

http://www.wikidata.org/entity/Q28250818

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

name

Psilocybin can occasion mystic ...... ing and spiritual significance

@ast

Psilocybin can occasion mystic ...... ing and spiritual significance

@en

Psilocybin can occasion mystic ...... ing and spiritual significance

@nl

type

label

Psilocybin can occasion mystic ...... ing and spiritual significance

@ast

Psilocybin can occasion mystic ...... ing and spiritual significance

@en

Psilocybin can occasion mystic ...... ing and spiritual significance

@nl

prefLabel

Psilocybin can occasion mystic ...... ing and spiritual significance

@ast

Psilocybin can occasion mystic ...... ing and spiritual significance

@en

Psilocybin can occasion mystic ...... ing and spiritual significance

@nl

P1433

Q28250818-8D74A072-1A7C-46EA-BECE-B131B01EE72D

P1476

Q28250818-BD90631F-0D69-4E8A-B432-BCB8561EE9E6

P2093

Q28250818-1DFE6937-8A3C-4395-8AFF-B9C40EA46E38

Q28250818-2E20F0D5-E4DA-4176-8103-A870A7040C5B

Q28250818-6FEF92F6-1196-485A-ADD7-3F9713866A91

Q28250818-F071BF4B-651F-4F29-A746-53A08F8B44B6

P2860

Q28250818-0161493E-65E3-4CB6-9860-D477420C8220

Q28250818-EA841FA7-35C7-4878-A0C6-09612AA492B4

P2888

Q28250818-6A46AAE9-AFA0-4B32-9417-57A6B29BB2DE

P304

Q28250818-991459B6-ACCE-427E-A064-A6FBCE21BBF7

P31

Q28250818-EF64AA5A-C6C3-4942-B1BE-294FF8756060

P3181

Q28250818-9DE1A07B-B75C-477E-89A1-021B20ADA6DA

P356

Q28250818-0AFA05F2-4DE9-472C-B71A-0D846D868C3B

P407

Q28250818-F87B1894-8341-4525-9A4C-E5E1EA5CDEB5

P433

Q28250818-122838A0-A976-4124-A384-7447F434E705

P478

Q28250818-8C0CB142-10F9-47EB-951D-B4D9AC711F0A

P577

Q28250818-ADC3293A-9678-4225-940E-B72EB461133D

P5875

Q28250818-B68A5CAE-07C7-4FF1-A59E-06FDB838A34C

P6179

Q28250818-66B4DD0C-96DD-4BAE-829C-C86C8D27ECC9

P698

Q28250818-D91CBEFF-FE75-43F6-80AD-CFA53DBCB60B

P3181

P356

S00213-006-0457-5

P1433

Psychopharmacology

P1476

Psilocybin can occasion mystic ...... ing and spiritual significance

@en

P2093

R Jesse

http://www.w3.org/2001/XMLSchema#string

R R Griffiths

http://www.w3.org/2001/XMLSchema#string

U McCann

http://www.w3.org/2001/XMLSchema#string

W A Richards

http://www.w3.org/2001/XMLSchema#string

P2860

Experimental psychiatry. V. Psilocybine, a new psychotogenic drug.

Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.

P2888

s00213-006-0457-5

P304

268-83; discussion 284-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4498127

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S00213-006-0457-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

187

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235984074

http://www.w3.org/2001/XMLSchema#string

P6179

1014219552

http://www.w3.org/2001/XMLSchema#string

P698

16826400

http://www.w3.org/2001/XMLSchema#string